Recruiting PHASE3 INTERVENTIONAL 2-arm NCT06675214

Under Whole-course of Immunotherapy, Gradient Fractionated RT with CCT Versus CFRT with CCT for LANPC Who Achieved PR Post Induction Chemotherapy.

Under Whole-course of Immunotherapy, Gradient Fractionated Radiotherapy with Concurrent Chemotherapy Versus Standard Fractionated Radiotherapy with Concurrent Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma Who Achieved Partial Response After Induction Chemotherapy: a Randomized, Open-label, Multicenter, Phase III Trial.

Sponsor: Sun Yat-sen University

Conditions De-escalation Therapy Nasopharyngeal Carcinoma

Interventions Cisplatin-based induction chemotherapy Concurrent Chemotherapy Full course of PD-1/PD-L1 blockades Gradient Fractionated IMRT Standard-dose IMRT

Updated 1 time since 2024 Last updated: Nov 3, 2024 Started: Jul 30, 2024 Primary completion: Jul 31, 2027 Completion: Jul 31, 2030

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on De-escalation Therapy and Nasopharyngeal Carcinoma, this trial is actively recruiting participants. The trial is conducted by Sun Yat-sen University and has accumulated 1 data snapshot since 2024. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

1 version recorded

Recruiting — PHASE3 [monthly]

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sun Yat-sen University

Data source: Sun Yat-sen University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Zhuhai, China